Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.

Publication Name: The Breast

Author(s): Kathy S Albain, Soonmyung Paik, Laura van ’t Veer

Background: Multigene assays performed on the primary tumors from women with non- metastatic breast cancer provide useful prognostic information and discriminate excellent versus poor outcome potential in diverse clinical scenarios. Recently, analyses were conducted to determine if these assays predict … Continued

MammaPrint the 70-gene signature – another milestone in personalized medical care for breast cancer patients.

Publication Name: Expert Review, Diagnostic Profile

Author(s): EA Slodkowska and JS Ross

The MammaPrint™ assay (Agendia BV, The Netherlands) is the first fully commercialized microarray-based multigene assay designed to individualize treatment for patients with breast cancer. MammaPrint, the first assay to be cleared at the 510(k) level by the US FDA’s new in … Continued

Clinical Application of the 70-Gene Profile: The MINDACT Trial

Publication Name: Journal of Clinical Oncology

Author(s): Cardoso F1, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ

The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid … Continued

Feasibility of using core-needle biopsies for the 70-gene prognosis signature

Publication Name: Poster

Author(s): J Mayordomo, A Modollel, C Rolfo, S Morales, A Glas, A Floore, E van Lienen, F de Snoo, L Stork-Sloots

A 70-gene microarray prognosis signature was previously discovered to improve the selection of patients with breast cancer for adjuvant therapy.(1,2) This diagnostic test known as “MammaPrint” was recently validated in an independent cohort and implementation was shown to be feasible … Continued

Use of a 70-Gene Signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Publication Name: Lancet Oncology

Author(s): Jolien M Bueno-de-Mesquita MD, Prof Wim H van Harten MD, Valesca P Retel MSc, Laura J van 't Veer PhD, Prof Frits SAM van Dam PhD, Kim Karsenberg MSc, Kirsten FL Douma MSc, Harm van Tinteren PhD, Johannes L Peterse MD, Jelle Wesseling MD, Tin S Wu MSc, Douwe Atsma BSc, Prof Emiel JT Rutgers MD, Guido Brink BSc, Arno N Floore BSc, Annuska M Glas PhD, Rudi MH Roumen MD, Frank E Bellot MD, Cees van Krimpen MD, Prof Sjoerd Rodenhuis MD, Prof Marc J van de Vijver MD, Dr Sabine C Linn MD

Background: A microarray-based 70-gene prognosis signature [MammaPrint] might improve the selection of patients with node-negative breast cancer for adjuvant systemic treatment. The main aims of this MicroarRAy PrognoSTics in Breast CancER (RASTER) study were to assess prospectively the feasibility of … Continued

Analysis of the MammaPrint breast cancer assay in an older US General Hospital population.

Publication Name: Poster, AACR 2007

Author(s): Ben S. Wittner, Dennis C. Sgroi, Paula D. Ryan, Tako J. Bruinsma, Annuska M. Glas,

Breast cancer patients with similar pathological staging can have markedly different rates of disease-free and overall survival. A key challenge in breast cancer management is to accurately determine a patient’s risk of developing distant metastasis at the time of primary … Continued

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

Publication Name: BMC Genomics

Author(s): Glas AM, Floore A, Delahaye LJMJ et al.

Background: A 70-gene tumor expression profile was established as a powerful predictor of disease outcome in young breast cancer patients. This profile, however, was generated on microarrays containing 25,000 60-mer oligonucleotides that are not designed for processing of many samples … Continued

Mammary gland biology and breast cancer. Conference on Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer Progression

Publication Name: EMBO Reports

Author(s): Sharon F McGee, Fiona Lanigan, Emer Gilligan,and Bernd Groner

Introduction:  As a model system for biological investigations, the mouse mammary gland is as versatile as the Drosophilaeye. This comparison does not reflect any ignorance of comparative anatomy, but rather it highlights the multitude of possibilities that the mammary gland … Continued

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

Publication Name: Journal of the National Cancer Institute

Author(s): Marc Buyse, Sherene Loi, Laura van’t Veer, Giuseppe Viale, Mauro Delorenzi, Annuska M. Glas, Mahasti Saghatchian d’Assignies, Jonas Bergh, Rosette Lidereau, Paul Ellis, Adrian Harris, Jan Bogaerts, Patrick Therasse, Arno Floore, Mohamed Amakrane, Fanny Piette, Emiel Rutgers, Christos Sotiriou, Fatima Cardoso, Martine J. Piccart

Background: A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients. Methods: Patients (n = 307, with 137 events after a … Continued

Concordance among Gene-Expression– Based Predictors for Breast Cancer

Publication Name: The New England Journal of Medicine

Author(s): Cheng Fan, M.S., Daniel S. Oh, Ph.D., Lodewyk Wessels, Ph.D., Britta Weigelt, Ph.D., Dimitry S.A. Nuyten, M.D., Andrew B. Nobel, Ph.D., Laura J. van’t Veer, Ph.D., and Charles M. Perou, Ph.D.

Background Gene expression profiling studies of primary breast tumors performed by different laboratories have resulted in the identification of a number of distinct prognostic profiles, or gene sets, with little overlap in terms of gene identity. Methods To compare the … Continued